Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 5/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162298 | 0.81 | VHL (0.41) | KMT2ANOTUM | |
| SCHEMBL11001522 | 0.75 | MAOA (0.35) | POLBKMT2A | |
| SCHEMBL2792592 | 0.74 | HTR2B (0.39) | POLBKMT2ANOTUM | |
| SCHEMBL1844609 | 0.72 | NPC1 (0.48) | USP2ALPLPOLBALPIKMT2A | |
| SCHEMBL11469002 | 0.71 | KMO (0.33) | KMO | |
| SCHEMBL11001305 | 0.71 | KDM4E (0.44) | KMT2A | |
| SCHEMBL11002734 | 0.71 | RYR2 (0.46) | KMT2A | |
| SCHEMBL8834341 | 0.70 | FABP4 (0.45) | FABP4 | |
| SCHEMBL8834452 | 0.70 | FABP4 (0.45) | FABP4 | |
| SCHEMBL5956898 | 0.70 | CA2 (0.38) | PSMD14USP2PLA2G1BALPLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-0011426-A1 | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same | PFIZER INC. (US) | 1980-05-28 | — | — | EP | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| JP-2005000826-A | TANK CLEANING SYSTEM AND TANK CLEANING METHOD | NIPPON OIL STAGING TERMINAL CO LTD | 2005-01-06 | — | — | JP | disclosed |
| US-4210663-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OF DIABETIC CATARACTS, NEUROPATHY OR RETINOPATHY | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4210663-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OF DIABETIC CATARACTS, NEUROPATHY OR RETINOPATHY | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0011426-A1 | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same | PFIZER INC. (US) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | FABP4 3579/4885PSMD14 3640/4885USP2 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.